# US 2013/0156775 A1 · Chlamydia trachomatis antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156775 A1
- Document ID: US20130156775A1
- Status: Published application
- Kind: A1
- Application number: 13/344,490
- Filed: 2012-01-05
- Published: 2013-06-20
- Earliest claimed: 1998-12-18
- Inventors: Giulio Ratti
- Web page: https://patentgrep.com/patent/US20130156775A1

## CPC

- A61K 39/118: Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- C07K 14/295: from Chlamydiales (O)
- C07K 16/125: {from Chlamydiales (O)}
- G01N 33/56927: {Chlamydia}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/53: {DNA (RNA) vaccination}
- G01N 2333/295: from Chlamydiales (o)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Proteins encoded by Chlamydia trachomatis which are immunogenic in humans as a consequence of infection have been identified using Western blots of two-dimensional electrophoretic maps. Several known immunogens were identified, as were proteins not previously known to be immunogens, and proteins not previously reported as expressed gene products.

## Claims

### Claim 1

A method of eliciting a Chlamydia-specific immune response in a patient, the method comprises the step of administering to the patient an effective amount of an immunogenic composition selected from the group consisting of (i) an immunogenic protein comprising a Chlamydia trachomatis htrA protein having an N-terminal sequence as shown in SEQ ID NO:3; (ii) a nucleic acid encoding a Chlamydia trachomatis htrA protein having an N-terminal sequence as shown in SEQ ID NO:3; (iii) an antibody specific for a Chlamydia trachomatis htrA protein having an N-terminal sequence as shown SEQ ID NO:3; and (iv) combinations of (i), (ii) and (iii).

### Claim 2 (depends on 1)

The method of claim 1, wherein the immunogenic composition comprises an immunogenic protein comprising a Chlamydia trachomatis htrA protein having an N-terminal as shown in SEQ ID NO:3.

### Claim 3 (depends on 1)

The method of claim 1, wherein the immunogenic composition comprises a nucleic acid encoding a Chlamydia trachomatis htrA protein having an N-terminal sequence as shown in SEQ ID NO:3.

### Claim 4 (depends on 1)

The method of claim 1, wherein the immunogenic composition comprises an antibody specific for a Chlamydia trachomatis htrA protein having an N-terminal sequence as shown SEQ ID NO:3.
